What is Stellaromics?
Founded in Boston, Stellaromics is a pioneer in the field of spatial transcriptomics, dedicated to transforming how scientists visualize and analyze biological systems. The company's core innovation, STARmap (Spatially-resolved Transcript Amplicon Readout mapping), provides a breakthrough method for mapping three-dimensional transcription and translation patterns directly within native tissue samples. Unlike traditional methods that often lose spatial context, Stellaromics enables the visualization of gene expression in situ, offering a comprehensive view of cellular interactions. This capability is essential for identifying novel therapeutic targets and advancing precision medicine, positioning the company as a critical infrastructure provider for the global life sciences research community.
How much funding has Stellaromics raised?
Stellaromics has raised a total of $105M across 2 funding rounds:
Series A
$25M
Series B
$80M
Series A (2023): $25M with participation from Plaisance Capital Management
Series B (2025): $80M led by Catalyst4 and Stanford University Ventures
Key Investors in Stellaromics
Catalyst4
A business and HR consultancy firm that provides strategic planning and organizational development services to help companies navigate complex growth challenges.
Stanford University Ventures
The venture arm of Stanford University, focusing on supporting high-potential research-driven startups and academic spin-offs.
Plaisance Capital Management
An investment management firm that provides strategic capital to support the scaling of innovative technology and life science enterprises.
What's next for Stellaromics?
With the successful closure of this major enterprise-level funding, Stellaromics is poised to scale its operational capacity and expand its market reach. The strategic focus will likely center on enhancing the throughput of the STARmap platform and broadening its application across diverse therapeutic areas, including oncology and neurobiology. As the company transitions into this next phase of growth, the emphasis will remain on fostering collaborative partnerships with academic institutions and pharmaceutical entities to drive the adoption of spatial biology workflows. By maintaining its commitment to technical excellence and innovation, Stellaromics is set to play a central role in the future of genomic research and drug development.
See full Stellaromics company page
